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1. Introduction
The guideline represents a short version of the complete gui-
deline available as online supplement and at www.awmf 
.org. Information on “Epidemiology and etiology”, “Surgical 
and systemic treatment of cutaneous squamous cell carcinoma”, 
“Surveillance”, “Prevention” and “Occupational disease” can 
be found in part 2 of the short version of the guideline or in the 
long version. A full list of references and the analysis of evidence 
underlying the recommendations and statements, along with the 
conflicts of interest of the authors involved in the present guide-
line, are available in the long version and in the guideline report.
2. Methodology
At the launch event, the guideline group initially defined 
key questions. Following research required to address these 
questions, recommendations and statements were developed at 
the S3 level according to AWMF regulations. To classify the risk 
of bias pertaining to the relevant studies that were identified, 
the authors used the 2011 version of the Oxford Centre for 
Evidence-based Medicine system. Pursuant to AWMF regula-
tions, the methodology of the German Guideline Program in 
Oncology of the DKG, DKH and AWMF requires guideline 
authors to grade the recommendations as part of a formal con-
sensus procedure. This included nominal group processes and 
structured consensus conferences moderated by AWMF repre-
sentatives during which the recommendations were formally 
voted on by the mandate holders eligible to vote. Based on how 
many of them agreed with a given recommendation/statement, 
the strength of consensus was graded as shown in Table 1.
For each evidence-based statement and recommendati-
on, the level of evidence of the underlying studies is indicated 
in the guideline; recommendations also include an indication 
as to their strength (grade). Three grades of recommenda-
tions are distinguished herein, which is reflected by how the 
recommendations are worded (Table 2).
The criteria used for determining the grades of the 
recommendations are explained in the guideline report (see 
long version). Statements include presentations or explana-
tions of specific aspects or questions that do not immediately 
require any action. They are adopted in a formal consensus 
procedure, much in the same way as the recommendations; 
statements may be based either on study data or on expert opi-
nions. Statements or recommendations that were considered 
to require modifications based on consensus of the experts 
Summary
Actinic keratoses (AK) are common lesions in light-skinned individuals that can 
potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions 
may be associated with significant morbidity and constitute a major disease burden, 
especially among the elderly. To establish an evidence-based framework for clinical de-
cision making, the guideline “actinic keratosis and cutaneous squamous cell carcinoma” 
was developed using the highest level of methodology (S3) according to regulations 
issued by the Association of Scientific Medical Societies in Germany (AWMF). The 
guideline is aimed at dermatologists, general practitioners, ENT specialists, surgeons, 
oncologists, radiologists and radiation oncologists in hospitals and office-based set-
tings as well as other medical specialties involved in the diagnosis and treatment of pa-
tients with AK and cSCC. The guideline is also aimed at affected patients, their relatives, 
policy makers and insurance funds. In the first part, we will address aspects relating to 
diagnosis, interventions for AK, care structures and quality-of-care indicators.
Table 1 Strength of consensus based on the percentage of 
agreement in the consensus process.
Strength of consensus Percentage of agreement
Strong consensus > 95 % of voters
Consensus > 75–95 % of voters
Majority approval > 50–75 % of voters
Dissent < 50 % of voters
Table 2 Gradation of the strengths of recommendations.
Grade of recom-
mendations
Description Wording
A Strong recommendation Shall
B Recommendation Should
0 Open recommendation May
issued by the German Guideline Program in Oncology of the German Cancer Society 
(DKG), DKH and the Association of the Scientific Medical Societies in Germany (AWMF).
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involved are designated as “expert consensus”. No symbols 
or letters were used for the gradation of “expert consensus” 
items; the strength of the various consensus points is reflec-
ted by the wording used (shall/should/may) (Table 2).
3. Diagnosis
3.1.  Classification, definition and nomenclature 
of AK
Consensus-based recommendation
Expert consensus The term “actinic keratosis” shall be 
used.
Strong consensus (100 %)
Actinic keratoses (AK) are clinically and histomorpho-
logically identifiable skin lesions characterized by prolifera-
tion (hyperplasia) of atypical epidermal keratinocytes that 
have no basaloid phenotype. The cytomorphological and 
genetic changes in these atypical keratinocytes are similar 
to those seen in the neoplastic cells of invasive cutaneous 
squamous cell carcinoma (cSCC) developing in chronical-
ly UV-exposed skin. To date, there is insufficient evidence 
that histomorphological parameters have any clinical and/
or therapeutic relevance. Thus, any detailed and compre-
hensive documentation of certain criteria beyond stating 
the diagnosis and subtype appears to be unnecessary and 
not very useful.
Consensus-based recommendation
Expert consensus The following  histomorphological 
 variants should be specified if 
 detected: atrophic, hypertrophic, 
acantholytic, pigmented, lichenoid 
and bowenoid AK.
Strong consensus (100 %)
The histomorphological presentation of AK ranges from 
merely actinically damaged skin with initial atypia of single 
keratinocytes to complete replacement of the epidermis by 
atypical keratinocytes. The latter corresponds to epidermal 
carcinoma in situ; if the keratinocytes are highly atypical 
and pleomorphic, the lesion is referred to as Bowen’s disease. 
For further classification of this morphological spectrum, a 
three-stage classification scheme (keratinocytic intraepitheli-
al neoplasia, KIN I–III) has been proposed that is based on 
the classification used for cervical intraepithelial neoplasia, 
whose lesions are predominantly HPV-induced. This sug-
gests an analogy to cervical, vulvar, penile, anal or perianal 
intraepithelial neoplasia (the numbers correspond to the 
epithelial layers involved). However, this concept has been 
subject to widespread and controversial debate, given that 
invasive processes may occur at any stage and given that a 
three-stage classification system is naturally associated with 
a very high level of interobserver disagreement. Moreover, 
this concept has not resulted in any tangible clinical conse-
quences for everyday clinical practice.
3.2.  Classification, definition and nomenclature 
of cSCC
Consensus-based statement
Expert consensus cSCC is a malignant neoplasm of 
epidermal keratinocytes.  Lesions 
may show various degrees of 
 differentiation (see also WHO/UICC 
classification).
Strong consensus (100 %)
Consensus-based statement
Expert consensus In most cases, yet not necessarily, 
cSCC arises from intraepidermal pro-
liferation of atypical keratinocytes.
Strong consensus (100 %)
Consensus-based statement
Expert consensus A cSCC is considered to be invasive if 
there is histomorphological  evidence 
of disruption of the basement 
 membrane below an intraepidermal 
proliferation of keratinocytes in 
non-traumatized skin.
Consensus (87.5 %)
Consensus-based statement
Expert consensus Bowen’s disease is defined as in-
traepidermal proliferation of highly 
atypical, pleomorphic keratinocytes 
that involves the entire width of the 
epidermis. Bowen’s disease is thus a 
special variant that may evolve into 
invasive cSCC; the lesion then usually 
exhibits bowenoid differentiation (ple-
omorphic, poorly differentiated) and 
is referred to as Bowen’s carcinoma.
Strong consensus (100 %)
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Consensus-based statement
Expert consensus The following variants of cSCC can be 
distinguished based on histomorpho-
logical criteria (some of these variants 
are also included in the WHO/UICC 
classification):
– Adenosquamous cSCC
– Acantholytic cSCC (synonym: 
 adenoid or pseudoglandular 
cSCC)
– Bowen’s carcinoma/ cSCC with 
bowenoid differentiation
– Desmoplastic cSCC
– Keratoacanthoma-like cSCC/ 
 keratoacanthoma
– Lymphoepithelioma-like cSCC
– Pseudovascular cSCC (synonym: 
pseudoangiosarcomatous or 
 pseudoangiomatous cSCC)
– Spindle cell cSCC (synonym: 
 sarcomatoid cSCC)
– Verrucous cSCC (synonym: 
 epithelioma cuniculatum)
Strong consensus (100 %)
Consensus-based recommendation
Expert consensus The classification of cSCC should be 
based on histological and clinical para-
meters according to the current TNM 
systems of UICC or AJCC.
Strong consensus (100 %)
As special variant of cSCC, keratoacanthoma usually 
runs a benign course. There is no definitive clinical differenti-
ation from cSCC. Although keratoacanthoma is readily cha-
racterized by its rapid growth and dome-shaped appearan-
ce, unequivocal clinical and/or histological differentiation 
is challenging and at times even arbitrary. Characteristic 
features include a central keratotic plug, high degree of 
differentiation, distinct symmetry and a broad-based infilt-
ration pattern. The tumor has the ability to spontaneously re-
gress. Primary treatment and histological processing should 
be the same as for cSCC. In particular, this applies to pa-
tients at increased risk of metastasis. Verrucous cSCC is a 
particularly well-differentiated variant that is known to be 
associated with invasive growth but only rarely gives rise to 
distant metastasis. Other entities subsumed under this his-
tological diagnosis (according to WHO/UICC classification) 
include epithelioma cuniculatum, oral florid papillomatosis 
and so-called giant condyloma (Buschke-Löwenstein). Not 
yet included in the international classification is desmopla-
stic cSCC, which features abundant stroma and narrow 
cell strands and is characterized by distinctly infiltrative – 
occasionally perineural or perivascular – growth. Unlike 
other cSCC variants, this type is associated with high recur-
rence (about 25 %) and metastatic (about 10 %) rates.
Other than that, the WHO/UICC/AJCC classification 
can be used, which is particularly useful for very large cSCC 
tumors. Nevertheless, the classification of cSCC current-
ly available does not appear to meet all necessary require-
ments, as it provides differentiating information for only a 
very small percentage of tumors. Traditionally, lesions have 
been clinically categorized as low-risk (diameter ≤ 20 mm) 
and high-risk tumors (diameter > 20 mm) (clinical parame-
ter). However, there seems to be more evidence for using 
the vertical tumor thickness (measured histologically) as 
a parameter for classification as it allows for more accura-
te assessment of the metastatic risk. Depending on the pati-
ent population, the metastatic rate of cSCC is 3–6 %. A less 
favorable prognosis is observed in immunosuppressed patients 
following organ transplantation or high-dose chemotherapy. 
Desmoplastic cSCC is roughly 20 times more likely to locally 
recur than other cSCC variants. Local recurrences are consi-
dered to be prognostically unfavorable. In this context, it is 
unclear whether they themselves contribute to the worsening 
of the prognosis or whether they merely reflect the aggressive 
biological behavior of that particular cSCC variant [1].
3.3. Field cancerization
Consensus-based statement
Expert consensus There is no generally accepted 
 definition of field cancerization. Field 
cancerization refers to an area with 
multiple AK surrounded by evident 
UV-induced skin damage.
Strong consensus (100 %)
Field cancerization is clinically defined as an anato-
mical site with AK (or adjacent to them) and visible solar 
damage characterized by at least two of the following fin-
dings: telangiectasia, atrophy, dyspigmentation and a sand-
paper-like texture. It is unclear whether a clinically visible 
AK is a prerequisite for field cancerization to be diagnosed 
[2]. Patients with these features and AK are recommended 
to undergo either field-directed treatment or field-directed 
treatment in combination with lesion-directed treatment. 
In case of clinical signs of field cancerization but no actual 
AK, it is recommended to take educational or preven-
tive measures and to have patients monitor “the field” 
themselves [2].
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3.4.  Value of non-invasive diagnostic methods in 
the diagnosis of AK and cSCC
Consensus-based statement
Expert consensus The diagnosis is made by clinical 
 examination and inspection.
Strong consensus (100 %)
Consensus-based recommendation
Expert consensus Dermoscopy, confocal laser  scanning 
microscopy and optical coherence 
tomography may be used for the 
diagnosis of AK and cSCC if clinical 
findings are ambiguous.
Strong consensus (100 %)
3.5. Biopsy
Consensus-based statement
Expert consensus AK do not require histological 
 confirmation if clinical findings are 
characteristic.
Strong consensus (100 %)
Consensus-based recommendation
Expert consensus In recalcitrant and clinically 
 ambiguous cases, a biopsy shall be 
obtained.
Strong consensus (100 %)
AK do not require histological confirmation if the 
clinical findings are characteristic. Lesions that are clinically 
ambiguous, show signs of progression to cSCC, or whose 
biological behavior cannot be assessed should be biopsied. 
Histology shall also be obtained for AK that do not respond 
to adequate treatment.
Consensus-based recommendation
Expert consensus In case of clinical suspicion of cSCC or 
Bowen’s disease, histology shall also 
be obtained to distinguish the lesion 
from other benign or malignant 
neoplasms.
The maximum diameter of the 
tumor should be documented 
preoperatively.
Consensus (94.7 %)
Consensus-based statement
Expert consensus Depending on the clinical situation, 
punch biopsies, shave biopsies or 
 excisional biopsies are appropriate.
Consensus (94.7 %)
Consensus-based recommendation
Expert consensus If the clinical presentation is unam-
biguously consistent with cSCC, 
complete excision may be performed 
without prior biopsy.
Consensus (89.5 %)
In case of clinical suspicion of cSCC, obtaining a biopsy 
for histological evaluation is required. Depending on tumor 
size and therapeutic approach, appropriate options inclu-
de punch, incisional or shave biopsies or the tumor may be 
excised [3]. The clinical features of cSCC may vary, and lesi-
ons usually present as hyperkeratotic plaques, flat ulcerations 
with a peripheral rim or keratotic nodules with or without 
ulceration. cSCCs can develop de novo or from AK precur-
sor lesions (erythematous or hyperkeratotic patches and pla-
ques) as well as from AK or leukoplakic lesions. Given the 
variable clinical picture and the clinical and morphological 
overlap with various other tumor entities, and given that it is 
impossible to distinguish early invasive cSCC with disrupti-
on of the basement membrane from a hyperkeratotic AK 
solely on clinical grounds, histological examination should 
be performed prior to treatment initiation; this approach is 
particularly important, as it helps rule out other benign or 
malignant cutaneous neoplasms. If the overall clinical con-
text is unambiguous, it is justified to treat the lesion as if it 
were a confirmed case of cSCC.
3.6.  Parameters of the pathology report in 
patients with AK and cSCC
Consensus-based recommendation
Expert consensus In addition to the diagnosis of cSCC, 
the pathology report shall also 
include the following information:
– Histological tumor type (in case of 
special cSCC variants)
– Description of the histological 
depth of invasion in relation to 
the anatomic skin level involved 
(especially from Clark level V, 
corresponding to infiltration of the 
subcutis)
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Consensus-based recommendation
– Measurement of the depth of inva-
sion if greater than 2 mm (roughly 
corresponds to the diameter of the 
field of view [magnification x10])
– If present, information on 
 perineural spread, vascular 
 invasion or poor differentiation
– Information on whether the inva-
sive tumor component has been 
completely resected
Strong consensus (100 %)
3.7. Initial diagnostic workup
Consensus-based recommendation
Expert consensus If cSCC is suspected, the initial 
 examination shall include inspection 
of the entire skin.
Strong consensus (100 %)
3.7.1. Lymph node ultrasound
Consensus-based recommendation
Expert consensus Locoregional lymph node ultrasound 
shall be performed if locoregional 
metastases are suspected.
Locoregional lymph node ultrasound 
should be performed if there are risk 
factors.
Consensus (94.7 %)
3.7.2. Chest X-ray
Consensus-based recommendation
Expert consensus Routine chest X-ray shall not be 
performed if there is suspicion or 
evidence of locoregional or distant 
metastasis of cSCC.
Consensus (94.7 %)
3.7.3. Abdominal ultrasound
Consensus-based recommendation
Expert consensus Routine abdominal ultrasound shall 
not be performed if there is suspicion 
or evidence of locoregional or distant 
metastasis of cSCC.
Strong consensus (100 %)
3.7.4. Cross-sectional imaging
Consensus-based recommendation
Expert consensus If metastasis is suspected, cross-secti-
onal imaging shall be performed.
Strong consensus (100 %)
There are no studies investigating the routine use 
of cross-sectional imaging in the diagnostic workup of 
cSCC. Cross-sectional imaging studies should therefore be 
performed only in those cases in which clinical examination 
or other tests (e.g., lymph node ultrasound) have raised the 
suspicion of metastases. A discussion of the available imaging 
modalities is available in the long version.
4. Interventions for AK
4.1. Literature search and study selection
The evidence-based recommendations and statements pre-
sented herein were entirely based on prospective randomized 
controlled trials (RCTs) or systematic reviews and meta-ana-
lyses of RCTs that reported at least one of the previously de-
fined critical efficacy outcomes. These included (1) complete 
response, (2) partial response, (3) mean reduction in lesions 
per patient or randomized field of treatment, (4) improvement 
in the Investigator’s Global Improvement Index (IGII), and 
(5) improvement in the Participant’s Global Improvement 
Index (PGII). Detailed information on the critical efficacy 
endpoints including the definition of relevant subgroups is 
available in the long version.
4.2.  Indication for treatment and natural disease 
course
Consensus-based recommendation
Expert consensus The indication for treatment of AK 
should be based on clinical presentati-
on, risk factors (e.g., immunosuppres-
sion, cumulative UV exposure, number 
of lesions), comorbidities, life expec-
tancy and the patient’s preferences.
Consensus (93.8 %)
The likelihood with which AK may progress or spon-
taneously resolve without treatment has been the subject 
of intensive debate for years. Factors that potentially im-
pede any accurate analysis of relevant data include, among 
other factors, the necessity for long-term follow-up (at 
least 6–12 months), limited generalizability of results, si-
gnificant heterogeneity among study populations or the 
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fact that treatments may have been carried out in the me-
antime that affect the natural disease course. There are 
therefore only few cohorts in which the natural disease 
course was investigated without being influenced by inter-
ventions. Accordingly, data on the progression of AK to 
invasive cSCC vary widely, ranging from 0.03 % to 20 % 
per lesion and year [4–7]. On the other hand, there have 
also been reports of very high spontaneous remission ra-
tes between 15 % and 63 %. This begs the question as to 
whether every AK should be treated or whether watchful 
waiting is justifiable in a low-risk setting [8]. By contrast, 
it has been reported that roughly 60 % of invasive cSCC 
originate from AK lesions [5]. It has been shown that spon-
taneous regression rates are lower in cases in which a given 
field features multiple AK and signs of field cancerization 
[7]. What is more, recent studies on the pathogenesis of 
AK suggest that even early (i.e. clinically and histologically 
discreet) lesions may evolve into cSCC and that this does 
not require a gradual evolution through the various disea-
se stages (moderate and eventually hyperkeratotic AK) [9]. 
These findings render it difficult to assess which lesions 
are at high risk of transformation to invasive cSCC and 
which are not. Even though the various studies differ – as 
described above – in terms of patient and tumor characte-
ristics, there are risk factors and risk populations whose 
rates of disease progression are likely to be significantly 
higher. Such factors include immunosuppression, history 
of non-melanoma skin cancer, and cumulative UV expo-
sure. The number of existing lesions is likewise an import-
ant indicator of the individual risk of developing invasive 
cSCC. Against this background, a watch-and-wait appro-
ach should be viewed critically. Ultimately, the general 
indication for treatment is also guided by the patient’s life 
expectancy, comorbidities and preferences.
4.3. Principles of treatment
Given the multitude of options available for the treatment 
of AK, the choice of treatment may be difficult in everyday 
clinical practice. Direct comparison of the various inter-
ventions is frequently possible only to a limited extent, as 
many treatment modalities have not been studied in a head-
to-head setting. While network meta-analyses do allow 
for estimating therapeutic effects despite the lack of direct 
comparative studies, they frequently focus on merely one 
endpoint (e.g., complete patient clearance), so that import-
ant information may be lost. The data obtained through 
network meta-analyses is therefore insufficient for defini-
tive treatment decisions in everyday clinical practice, given 
that they may not provide information on tolerability or 
cosmetic outcomes [10, 11].
The choice of appropriate treatment is guided by 
patient-, lesion- and treatment-specific factors [12]. 
Patient- related factors include age, comorbidities, 
immunosuppression, comedication, patient’s wishes and 
preferences, and adherence to treatment. Lesional aspects 
comprise the number of AK, site (scalp, face, extremities, 
trunk), clinical presentation (Olsen classification, hyperke-
ratotic lesions) as well as the size of the field affected. In 
clinical practice, it is not always possible to make a clear 
and unambiguous distinction between multiple AK and 
field cancerization, and this is rendered even more difficult 
due to the lack of a generally accepted definition of field 
cancerization.
The long version of these guidelines contains detailed 
information on the factors on which treatment decisions 
are based and on the various therapeutic approaches to AK. 
Lesion- and field-directed treatments for AK are shown in 
Table 3. Factors to be considered in the choice of treatment 
for AK are provided in Table 4 [12].
4.4. Combination treatment
Consensus-based recommendation
Expert consensus A combination of field-directed and 
lesion-directed treatments may be 
offered.
Strong consensus (100 %)
Table 3 Lesion-directed and field-directed treatments 
for AK.
Primarily lesion- 
directed treatments
Primarily field-directed 
 treatments
Cryosurgery Peels
Surgical procedures Dermabrasion
Photodynamic therapy
(patch PDT)
Photodynamic therapy
Topical agents
(5-fluorouracil in 
 salicylic acid 10 % 
 solution)
Topical agents
(diclofenac sodium 3 % in 
hyaluronic acid 2.5 % gel)
(5-fluorouracil 5 % cream)
(5-fluorouracil in salicylic acid 
10 % solution)
(ingenol mebutate gel)
(imiquimod 5 % cream)
(imiquimod 3.75 % cream)
Laser devices Ablative laser devices
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Table 4 Factors to be considered in the choice of treatment 
for AK (modified after [12]).
Patient-related 
factors
Lesional factors Treatment- 
related factors
Age Number of lesions Lesion-directed or 
field-directed
Preference 
in terms of 
 treatment
Size of the 
 affected area
Treatment 
 modality 
( interventional, 
surgical, topical 
agents)
Comorbidities Site (scalp, 
face, trunk, 
 extremities)
Treatment 
 duration
Individual risk 
(immunosup-
pression, organ 
transplantation)
Clinical pre-
sentation and 
 demarcation
Effectiveness
Adherence/ 
compliance
Field 
 cancerization
Side effects and 
tolerability
Social 
 environment and 
resources
Self or third-party 
application
Ability to self- 
apply
Treatment costs
There is a large number of interventions available for 
the treatment of AK, which are frequently combined in cli-
nical practice. Given the great heterogeneity among studies 
in terms of dosage, combination protocols used and outco-
mes investigated, sequential treatment combinations were 
not systematically evaluated or analyzed. Nevertheless, as 
various interventions are commonly combined in clinical 
practice, a consensus-based recommendation is presen-
ted herein. This recommendation is based on the rationa-
le that the combination of different interventions is able 
to utilize the individual benefits of the various procedu-
res and thus create potential synergistic effects through 
different mechanisms of action. Clinical experience has 
shown that combinations consisting of a field-directed 
and an ablative procedure are well tolerated. In particu-
lar, lesion-directed pretreatment of a thick hyperkeratotic 
AK using an ablative procedure may be combined with 
subsequent field treatment, as this allows for fast and ef-
fective treatment of both clinically manifest and subclinical 
lesions. Conversely, even after primary field-directed treat-
ment, any remaining AK may be effectively treated with a 
lesion-directed approach.
4.5. Ablative modalities
4.5.1. Cryosurgery
Evidence-based recommendation
Grade of recom-
mendation
B
Cryosurgery should be offered for 
single or multiple grade I–III AK 
(Olsen classification) in immuno-
competent individuals.
Level of evidence
2
De novo research
Strong consensus (100 %)
4.5.2. Surgical procedures
Consensus-based recommendation
Expert consensus Surgical removal of grade I–III 
AK (Olsen classification) (e.g,. by 
 curettage, shave excision or complete 
excision) should be offered for single 
lesions in immunocompetent and 
 immunosuppressed patients.
Strong consensus (100 %)
While surgical removal of AK is a commonly employed 
treatment option in clinical practice, there is no evidence 
from RCTs. Our literature search – including systematic re-
views and meta-analyses from various databases – failed to 
identify any RCTs on surgical procedures [13, 14]. On the 
other hand, however, there is long-standing experience in the 
use of surgery for individual, clinically well-circumscribed 
lesions. Depending on the clinical context, suitable proce-
dures include curettage, shave biopsy and complete excisi-
on, and these techniques may be considered equivalent. The 
great advantage of surgical methods is that they allow for 
subsequent histological examination, especially to rule out 
invasive cSCC in clinically ambiguous cases.
4.5.3. Chemical peels
Evidence-based statement
Level of evidence
2
Current data do not allow any recom-
mendations for the treatment of AK 
with chemical peels.
De novo research
Strong consensus (100 %)
4.5.4. Dermabrasion
The effect of dermabrasion is based on mechanical removal 
of the superficial skin layers down to the dermoepidermal 
junction using a motorized handheld device (fraise). Used 
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for field-directed treatment of AK, dermabrasion is a relati-
vely old procedure. No RCTs on mechanical dermabrasion 
were identified. Further information on dermabrasion in the 
treatment of AK can be found in the long version of the 
guideline.
4.5.5. Laser treatment
4.5.5.1. Ablative laser treatment
Evidence-based recommendation
Grade of 
recommendation  
0
Ablative laser treatment may be 
 offered for single or multiple 
 grade I–III AK (Olsen classification) 
as well as for field cancerization in 
immunocompetent patients.
Level of evidence
2–3
De novo research
Consensus (92.3 %)
4.5.5.2. Non-ablative laser treatment
Consensus-based recommendation
Expert consensus Non-ablative laser treatment may be 
offered for single or multiple grade I–
II AK (Olsen classification).
Strong consensus (100 %)
4.6. Topical drugs
4.6.1. Diclofenac
Evidence-based recommendation
Grade of recom-
mendation
B
Treatment with diclofenac sodium 
3 % in hyaluronic acid 2.5 % gel 
should be offered for single or 
multiple grade I–II AK (Olsen clas-
sification) in immunocompetent 
individuals.
Level of evidence
1
De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation
B
Field-directed treatment with diclo-
fenac sodium 3 % in hyaluronic 
acid 2.5 % gel should be offered for 
field cancerization.
Evidence-based recommendation
Level of evidence
1
De novo research
Strong consensus (100 %)
4.6.2. 5-fluorouracil (5-FU)
Evidence-based recommendation
Grade of recom-
mendation
B
5-fluorouracil 5 % cream should be 
offered for the treatment of single 
and multiple grade I–II AK (Olsen 
classification).
Level of evidence
1
De novo research
Consensus (88.2 %)
Evidence-based recommendation
Grade of recom-
mendation
B
Field-directed treatment with 
5- fluorouracil 5 % cream should be 
offered for field cancerization.
Level of evidence
2–3
De novo research
Consensus (93.3 %)
Evidence-based statement
Level of evidence
2
There is evidence for the efficacy of 
5-fluorouracil 0.5 % cream in single 
and multiple grade I–II AK ( Olsen 
classification). However,  there 
is currently no approval for this 
 concentration in Germany.
De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation
B
5-fluorouracil 0.5 % in salicylic 
acid 10 % solution should be 
offered for single or multiple gra-
de I–II AK ( Olsen classification) as 
well as for field cancerization in 
 immunocompetent individuals.
Level of evidence
2
De novo research
Strong consensus (100 %)
Guideline 
285© 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2020/1803
4.6.3. Ingenol mebutate
Evidence-based recommendation
Grade of recom-
mendation
B
Field-directed treatment using 
 ingenol mebutate should be offered 
for single or multiple grade I–II AK 
(Olsen classification) as well as for 
field cancerization.*
Level of evidence
1–2
De novo research
Strong consensus (100 %)
*In coordination with the European Medicines Agency (EMA), the 
pharmaceutical company LEO Pharma decided to suspend market 
authorization for Picato® (ingenol mebutate) in January 2020, and to 
no longer supply Picato® to German pharmacies. Given the potenti-
al increased risk of skin cancer in areas previously treated with Pica-
to®, the agent should no longer be prescribed or used. The authors 
of the guideline therefore no longer recommend the use of ingenol 
mebutate for the treatment of AK.
4.6.4. Imiquimod
Evidence-based recommendation
Grade of recom-
mendation
B
Field-directed treatment using imi-
quimod 5 % cream should be offered 
for single or multiple grade I–II AK 
(Olsen classification) as well as for 
field cancerization in immunocom-
petent individuals.
Level of evidence
1
De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation
B
Lesion-directed treatment with imi-
quimod 5 % cream should be offered 
for single grade I–II lesions (Olsen 
classification).
Level of evidence
2
De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation
B
Field-directed treatment using 
 imiquimod 3.75 % cream should be 
offered for multiple grade I–II AK 
( Olsen classification) as well as for field 
cancerization of the face or scalp in 
immunocompetent individuals.
Level of evidence
2
De novo research
Strong consensus (100 %)
4.6.5. Conventional photodynamic therapy
Evidence-based recommendation
Grade of recom-
mendation
B
Conventional photodynamic thera-
py with 5-aminolevulinic acid or its 
methyl ester (5-ALA or MAL) should 
be offered for single or multiple 
grade I–II AK (Olsen classification) 
and for field cancerization.
Level of evidence
1
De novo research
Strong consensus (100 %)
The principle of photodynamic therapy (PDT) is based 
on the application of photosensitizing substances. These 
photosensitizers selectively accumulate in atypical epidermal 
keratinocytes and are subsequently activated by exposure to 
light of a suitable wavelength. Photochemical and photophy-
sical processes give rise to the formation of reactive oxygen 
species (ROS), which lead to cell damage and subsequently 
cell death in precancerous skin lesions. Photosensitizers com-
monly used for the treatment of AK are 5-aminolevulinate 
(ALA) and its methyl ester, methyl aminolevulinate (MAL). 
A precursor (prodrug) of endogenous heme synthesis, ALA 
is converted to photoactive porphyrins in the skin, such as 
protoporphyrin IX.
4.6.6. Daylight photodynamic therapy
Evidence-based recommendation
Grade of recom-
mendation
B
Field-directed treatment using 
MAL in combination with daylight 
( daylight MAL-PDT) should be 
 offered for non-pigmented single 
or multiple grade I–II AK (Olsen 
classification) as well as for field 
cancerization of the face and scalp in 
immunocompetent individuals.
Level of evidence
2–3
De novo research
Strong consensus (100 %)
A new approach and approved for treatment since 2015, 
daylight PDT (same indication as conventional PDT) involves 
widespread application of the photosensitizer (MAL) to the 
face and scalp after prior application of a chemical UV filter 
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and removal of keratotic debris. Subsequently, the patient is 
exposed to daylight for two hours in suitable weather con-
ditions (April–September, outside temperature > 10°C, sky 
may be cloudless or overcast, no rain). One advantage of day-
light PDT is that it is associated with significantly less pain 
ful sensation than conventional PDT.
4.6.7. Other topical agents
Evidence-based statement
Level of evidence
2
Current data does not conclusively al-
low for colchicine, difluoromethylor-
nithine, canola phenolic acid,  topical 
nicotinamide or UV filters to be re-
commended as treatment for AK.
De novo research
Consensus (87.5 %)
Evidence-based recommendation
Grade of recom-
mendation
B
Given the lack of evidence for their 
benefit, birch bark extracts and 
glucans shall not be used for the 
 treatment of grade I–III AK.
Level of evidence
2–3
De novo research
Strong consensus (100 %)
4.7. Retinoids
Evidence-based statement
Level of evidence
2–3
Current data does not allow for 
 topical or systemic retinoids to be 
 recommended as treatment for AK.
De novo research
Strong consensus (100 %)
4.8. Treatment in immunosuppressed patients 
and organ transplant recipients
Evidence-based recommendation
Grade of recom-
mendation
B
Treatment with photodynamic the-
rapy with MAL in combination with 
illumination by an artificial red-light 
source (630 nm) should be offered 
for single or multiple grade I–II AK 
(Olsen classification) as well as for 
field cancerization in immunosup-
pressed patients.
Evidence-based recommendation
Level of evidence
3
De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation
0
Field-directed treatment with imi-
quimod 5 % cream may be offered 
to immunosuppressed patients with 
multiple grade I–II AK (Olsen classifi-
cation) as well as with field canceriz-
ation. The missing approval has to be 
considered here.
Level of evidence
2
De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation
B
Treatment with diclofenac sodium 
3 % in hyaluronic acid 2.5 % gel 
should be offered to immuno-
suppressed patients with single 
or multiple grade I–II AK (Olsen 
 classification) as well as with field 
cancerization.
Level of evidence
3
De novo research
Strong consensus (100 %)
Patients on long-term immunosuppressive medication 
exhibit significantly increased cSCC-related morbidity and 
mortality than immunocompetent control groups [15]. Key 
interventions in these patients include early modification 
of immunosuppressive therapy by eliminating azathiopri-
ne from the regimen and switching to an mTOR inhibitor, 
and using the preventive effects of UV protection and vita-
min B6 on AK progression, which also apply to immuno-
suppressed patients. In this context, early treatment of AK 
– as secondary prevention – has also been shown to play an 
increasingly pivotal role. Such treatment not only has to be 
effective, it is also essential to consider potential interactions 
the chosen field-directed approach might be associated with 
in terms of immunosuppression and transplant safety (i.e., 
signs of graft rejection).
4.9. Summary and balanced presentation of 
approved treatment options for AK
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4.10. Preventive measures for AK
See chapter 3 (primary prevention) and chapter 4 (secondary 
prevention) of the S3 guideline for the ‘Prevention of Skin 
Cancer’ [16].
5. Care structures
The first German skin cancer center was established in Hei-
delberg in 2009. Until the end of 2018, a total of 63 centers 
had been certified. Certification occurs in two phases:
 Review of the data collection form for skin cancer cen-
ters (download www.onkozert.de) by two specialized 
auditors. The form is then returned to the respective 
center noting deviations or suggestions for improvement 
(evaluation of the data collection form).
 Audit performed by the same two auditors who evalua-
ted the data collection form. Not only is the respective 
center visited but also cooperating departments.
Further information on the provision of care at skin 
cancer centers is available in the long version of the guideline.
6. Quality-of-care indicators
Further information on quality-of-care indicators (Table 5) 
at skin cancer centers is available in the long version of the 
guideline.
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